For citations:
Ivakhnenko О.I., Ryazhenov V.V., Falaleeva N.A. Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2024;17(1):5-21. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.237
Views PDF (Rus): 574
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 